series-a
Stage
2018
Founded
1
Investors
About
Xinnate is a clinical-stage pharmaceutical company developing next-generation therapies built on proprietary peptide technology designed to restore balance in dysfunctional wound healing, particularly for Epidermolysis Bullosa and other inflammatory skin disorders.
Explore Xinnate's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.